I do not have access to the content of the article "Direct-Acting Antiviral Agents in Hepatitis C-Associated Indolent Lymphomas" from the New England Journal of Medicine (2026), so I cannot create a summary based solely on verified facts from it. The available search results describe general information about direct-acting antiviral agents (DAAs) in hepatitis C, but not the specific findings of this article on indolent lymphomas[1][2][3].